Latest revenue
$1.17B
as of 2026-03-31
Latest net income
$206.0M
as of 2026-03-31
Net margin
17.6%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $39.45B
- Enterprise value
- $39.45B
- P/E (trailing)
- 125.7×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $495.55
- 52-wk low
- $284.28
- Beta
- —
- Shares out
- 132.6M
5-year trend
About ALNY
Business description and risk factors will appear here once ALNY's latest filing is fully ingested.
Profitability
Operating margin
13.5%
271.7%Net margin
8.4%
168.3%Return on equity
39.8%
109.6%Return on assets
6.3%
196.3%Leverage
Debt / equity
5.29×
91.5%Long-term debt / equity
0.00×
100.0%Debt / assets
84.1%
14.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $1.17B | +96.4% | $206.0M | +1228.7% | 17.6% |
Q4 2025 2025-12-31 | $1.10B | +84.9% | $270.9M | +423.5% | 24.7% |
Q3 2025 2025-09-30 | $1.25B | +149.3% | $127.3M | +214.1% | 10.2% |
Q2 2025 2025-06-30 | $773.7M | +17.3% | $-66.3M | -292.4% | -8.6% |
Q1 2025 2025-03-31 | $594.2M | +20.2% | $-18.3M | +72.3% | -3.1% |
Q4 2024 2024-12-31 | $593.2M | — | $-83.8M | — | -14.1% |
Q3 2024 2024-09-30 | $500.9M | -33.3% | $-111.6M | -175.5% | -22.3% |
Q2 2024 2024-06-30 | $659.8M | +107.0% | $-16.9M | +93.9% | -2.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ALNY — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$103.7M
Net activity
−$103.7M
Distinct insiders
9
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALNY
Institutional value
$23.53B
Total shares held
72.0M
Distinct holders
530
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Capital World Investors | 10.8M | $3.57B | — | New |
| 2 | BlackRock, Inc. | 10.4M | $3.46B | — | New |
| 3 | Capital Research Global Investors | 9.5M | $3.13B | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.5M | $2.15B | — | New |
| 5 | JPMORGAN CHASE & CO | 6.3M | $2.00B | — | New |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5.9M | $1.97B | — | New |
| 7 | BAILLIE GIFFORD & CO | 2.5M | $825.1M | — | New |
| 8 | Clearbridge Investments, LLC | 1.4M | $448.7M | — | New |
| 9 | Invesco Ltd. | 1.3M | $427.4M | — | New |
| 10 | Legal & General Group Plc | 934.9K | $309.3M | — | New |
| 11 | VANGUARD FIDUCIARY TRUST CO | 840.9K | $278.2M | — | New |
| 12 | DEUTSCHE BANK AG\ | 761.5K | $251.9M | — | New |
| 13 | FEDERATED HERMES, INC. | 687.8K | $227.6M | — | New |
| 14 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 677.5K | $224.2M | — | New |
| 15 | Bank of New York Mellon Corp | 491.2K | $162.5M | — | New |
| 16 | FRANKLIN RESOURCES INC | 470.4K | $155.6M | — | New |
| 17 | UBS Group AG | 458.9K | $151.8M | — | New |
| 18 | Swiss National Bank | 387.7K | $128.3M | — | New |
| 19 | DIMENSIONAL FUND ADVISORS LP | 384.2K | $127.1M | — | New |
| 20 | FIRST TRUST ADVISORS LP | 382.7K | $126.6M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALNY's latest filing finishes processing.